7 hasil untuk "Sumit Bhatnagar"
Menampilkan 1–7 · 0,46 detik · RSS
-
Artikel Jurnal
The role of optical coherence tomography in detecting and correcting stent malapposition during primary percutaneous coronary intervention: A case series and review of current practice
Primary percutaneous coronary intervention (PCI) is the gold standard for treating acute myocardial infarction (AMI). Stent malapposition, a complication more common in AMI due to plaque disruption and thrombus burden, increases the risks of stent thrombosis and restenosis. Angiography often misses…
-
Artikel Jurnal
Risk factor and clinical profile of significant left main coronary artery disease in high volume tertiary care hospital
Background: Left main coronary artery (LMCA) disease is a potentially fatal condition that may be cured if recognized it early. The goal of this research was to identify risk factors, clinical characteristics, and angiographic characteristics of patients with severe left main disease who had…
-
Artikel Jurnal
Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches
ABSTRACT A common challenge in conducting phase 1 studies that assess the impact of organ impairment on the pharmacokinetics of a drug is the recruitment of a demographically matched control group. The work presented here evaluated alternative approaches for generating control groups in these…
-
Artikel Jurnal
Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology
Antibody drug conjugates (ADCs) provide targeted delivery of cytotoxic agents directly inside tumor cells. However, many ADCs targeting solid tumors have exhibited limited clinical efficacy, in part, due to insufficient penetration within tumors. To better understand the relationship between ADC…
-
Artikel Jurnal
Upadacitinib: Mechanism of action, clinical, and translational science
Abstract Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases, including rheumatic, dermatologic, and…
-
Artikel Jurnal
Model‐Informed Paradigm in Drug Development—An End‐To‐End Case Study From Upadacitinib Development
ABSTRACT Model‐informed drug development (MIDD) entails applying quantitative approaches to assist with decision‐making during drug development and has been used for dose optimization, to inform clinical trial design, and to support clinical trial waivers. With increasing cost and competitiveness…
-
Artikel Jurnal
Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis
Abstract Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and non‐radiographic axial spondyloarthritis…